A retrospective analysis of patients with unresectable pancreatic cancer treated with combined transarterial intervention and three dimensional conformal radiotherapy
LIU Ling-xiao,JI Wei,WANG Jian-hua,WANG Xiao-lin,YAN Zhi-ping,ZENG Zhao-chong,LIN Gen-lai
DOI: https://doi.org/10.3969/j.issn.1007-3969.2011.01.009
2011-01-01
Abstract:Background and purpose:Pancreatic carcinoma is a kind of malignant disease with the rising tendency of incidence and poor prognosis.Little progress has been made on the treatment of advanced pancreatic carcinoma during the past 2 decades.The combined mordality for the unresectable pancreatic carcinoma is controversial.We retrospectively reviewed the clinical data and the results of transarterial intervention alone or transarterial intervention combined with radiotherapy,analyzed the prognostic factors for patients with unresectable pancreatic carcinoma.Methods:We retrospective analyzed 105 patients with locally advanced and metastatic pancreatic carcinoma.Univariate and multivariate statistical methods were used to determine significant prognostic factors and therapy program for overall survival(OS).Results:For all patients,the median survival time(MST) was 9.0 months,1-year and 2-year OS were 31.2% and 12.2% respectively.For the locally advanced vs phase Ⅳ patients,the MST,1-year,2-year OS were 9.1 vs 7.6 months,33.2% vs 29.3% and 14.7% vs 9.1% respectively.On univariate analysis,the number of interventional therapy,whether combined with radiotherapy or not,the choice of gemcitabine programs and primary tumor site were important factors for OS.For all 105 patients,the MST of patients who received multiple transarterial therapy was 4.9 months longer than those who had single therapy(12.5 vs 7.6 monthes,P=0.010).1-year and 2-year OS were 51.5% vs 22.2% and 20.7% vs 8.1%.The MST of patients who received combined therapy was 4.3 months longer compared with who had only interventional therapy(11.9 vs 7.6 monthes,P=0.003),1-year,2-year OS were 48.5% vs 21.8% and 27.7% vs 2.7%.The MST of patients who received gemcitabine programs was 2.2 months longer compared with who had other programs(9.8 vs 7.6 monthes,P=0.018),1-year,2-year OS were 37.5% vs 18.8% and 20.3% vs 3.1%.The MST of patients with pancreatic head cancer was 3.0 months longer compared with the patients whose cancer located in pancreatic body or tail(10.5 vs 7.5 monthes,P=0.031),1-year,2-year OS were 40.2% vs 22.0% and 6.3% vs 8.8%.On multivariate analysis,Interventional therapy combined radiotherapy was independent prognostic factor for OS,it could decrease death risk for all patients 46%(95%CI: 0.272-0.891,P=0.047).Conclusion:In the current study,transarterial intervention combined with radiotherapy can improve overall survival among patients with unresectable pancreatic cancer.